VISITING SPEAKERS PROGRAM IN ONCOLOGY
2014-2015
The McGill Continuing Professional Development Office has made available, webcasts of the presentations.

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Date(s)</th>
<th>Institution</th>
<th>Title(s) of Presentation(s)</th>
</tr>
</thead>
</table>
| Dr. Richard H. De Boer         | September 10-11 | Epworth Freemasons Hospital, Melbourne AUSTRALIA                             | • What’s New with Bone Targeted Agents and Practical Management of Potential Side Effects and Toxicities  
• Adjuvant Therapy Selection for Young Breast Cancer Patients /Management of the Low Risk HER2 Positive Patient  
• New Agents in the Management of Endocrine Resistance in Metastatic Breast Cancer |
| Dr. Brian Rini                 | September 17    | Cleveland Clinic, Lerner College of Medicine, Case Western Reserve University USA | • Challenges in Drug Development for Metastatic Renal Cell Carcinoma  
• Therapeutic Decision Making in Advanced Renal Cell Carcinoma: A 2014 Perspective |
| Dr. Caroline Robert            | October 8       | Institut Gustave Roussy FRANCE                                               | • Immunotherapies in Cancer  
• Immunothérapies et cancer |
| Dr. Winson Y. Cheung           | November 19-20  | University of British Columbia CANADA                                        | • Metastatic Pancreatic Cancer: A Closer Look at Newer Therapies |
| Dr. Christopher Sweeney        | February 11-12  | Dana-Farber Cancer Institute USA                                             | • Integrated Treatment of Prostate Cancer in CHAARTED universe |
| Dr. Lecia V. Sequist           | February 25-26  | Dana-Farber Cancer Institute USA                                             | • Molecularly Defined Lung Cancers – Who’s Who? |
| Dr. Mathias Rummel             | March 18-20     | Justus-Liebig University-Hospital GERMANY                                    | • An Update on the Latest Clinical Evidence for the Management of Hematological Malignancies |
| Dr. Christian Kollmannsberger  | April 1         | University of British Columbia CANADA                                        | • Latest Evidence in mRCC |
| Dr. Denis Soulières            |                 |                                                                               | • Recent Advances in Pancreatic Cancer  
• Advanced Pancreatic Cancer: A Case-Based Discussion |
| Dr. Malcolm Moore              | April 22        | University of Toronto CANADA                                                 | |
| Professor Michel Ducr \n| June 17-18 | Institut Gustave Roussy \n| FRANCE | • Nouveautés en cancer colorectal métastatique, notamment sur les thérapies ciblées  
• Role of Maintenance Therapy in mCRC and Current Clinical Evidence for Continued Anti-VEGF Inhibition Following First Progression in mCRC |
Dr. Richard H. De Boer  
Medical Oncologist  
Epworth Freemasons Hospital  
Melbourne, Australia

Wednesday, September 10, 2014

"What’s new with bone targeted agents and practical management of potential side effects and toxicities "

Montreal General Hospital  
1650 Cedar Avenue  
Room: D14-102  
12:00 pm - 01:00 pm

Learning objectives
- New approaches to management of bone health in cancer, e.g. breast, prostate, lung,
- Integration of bone targeted therapies in the treatment of osteoporosis in patients living with cancer.

"Adjuvant Therapy Selection for Young Breast Cancer Patients / Management of the low risk HER2 positive patient "

Hôpital Notre-Dame  
1560, Sherbrooke Street East  
Auditorium Deschamps  
Room I-1176-2  
05:00 pm - 06:00 pm

Learning objectives
- How young age influence on adjuvant treatment decisions,
- Chemotherapy role and non-chemotherapy strategies in younger patients.

Thursday, September 11, 2014

"New agents in the management of endocrine resistance in metastatic breast cancer "

Jewish General Hospital  
3755 ,Côte Ste-Catherine  
Room: E711  
12:30 pm - 01:30 pm

Learning objectives
- Endocrine resistance scope of the clinical problem ,
- Current treatment strategies and evidence,
- Emerging targeted therapies.
Dr. Brian Rini
Professor of Medicine
Cleveland Clinic Lerner
College of Medicine
Case Western Reserve University
Cleveland, Ohio

Wednesday, September 17, 2014

“Therapeutic Decision Making in Advanced Renal Cell Carcinoma: a 2014 Perspective”

Hôpital Cité de la Santé
1755, boulevard René Laennec, Laval
Room GS-011 — 08:00 am - 09:00 am
For videoconference, contact:
ast-jacques.csssl@ssss.gouv.qc.ca

“Challenges in Drug Development for Metastatic Renal Cell Carcinoma”

Hôpital Notre-Dame
1560, Sherbrooke Street East
Auditorium Deschamps
Room I-1176-2
05:00 pm - 06:00 pm

Learning objectives
- Sequencing agents (1st line, 2nd line, 3rd line)
- Treatment optimization (dose intensity, optimal structure/ support for AE management)
- How to Define progression and when to move to the next line of treatment
- Management of the non clear cell RCC patient
- Biomarker driven treatment decision making
- Potential resistance mechanisms in RCC

Hôpital Notre-Dame
1560, Sherbrooke Street East
Auditorium Deschamps
Room I-1176-2
05:00 pm - 06:00 pm

Learning objectives
- Correlation of PFS and OS in mRCC
- The importance of objective response rate in mRCC
- Are mRCC patients really living longer?

For more information or a complete description of these events, please visit our website at:
http://www.medicine.mcgill.ca/oncology/speakers/speakers_visitingspeakers.asp
VISITING SPEAKERS PROGRAM IN ONCOLOGY

Dr. Caroline Robert
Dermatology Division Chief
Gustave Roussy Institute
Villejuif, France

Wednesday, October 08, 2014

“Immunotherapies in Cancer”

Jewish General Hospital
3755, Côte Ste-Catherine
Room: E711
12:30 pm - 01:30 pm

“Immunothérapies et cancer”
(French talk)

Hôpital Notre-Dame
1560, Sherbrooke Street East
Auditorium Deschamps
Room L-1176-2
05:00 pm - 06:00 pm

Learning objectives

- Provide an overview of immune checkpoint inhibitors for the treatment of Cancer.
- Review the current and future immuno-oncology treatments for Metastatic Melanoma.
- Discuss the management of immune-related adverse events of immuno-oncology treatments

Learning objectives

- Fournir une vue d’ensemble du rôle des inhibiteurs des points de contrôle immunologiques dans le traitement du cancer.
- Passer en revue les traitements d’immunothérapie présentement utilisés et à venir dans le traitement du mélanome métastatique.
- Discuter de la prise en charge des effets indésirables de nature immunologique reliés à l’immunothérapie.
Dr. Winson Y. Cheung  
Medical Oncologist,  
British Columbia Cancer Agency  
Vancouver Centre Clinic  
Assistant Professor,  
UBC Division of Medical Oncology

Wednesday, November 19, 2014

“Metastatic Pancreatic Cancer: A Closer Look at Newer Therapies”

Jewish General Hospital  
3755 ,Côte Ste-Catherine  
Room:  E711  
12:00 pm - 01:00 pm

For videoconference registration:  
http://telesantemcgill.ca/fr/services/videoconference/event-details.asp?id=22831

Watch live @ www.vpsolution.tv/vspo
Problems / Questions:  514-813-4510

Hôpital Notre-Dame  
1560, Sherbrooke Street East  
Auditorium Deschamps  
Room I-1176-2  
05:00 pm - 06:00 pm

Watch live @ www.vpsolution.tv/vspo
Problems / Questions:  514-813-4510

Thursday, November 20, 2014

Sacré-Coeur Hospital  
5400 Blvd. Gouin East  
Room:  G-4115  
03:00 pm - 04:00 pm

For videoconference registration:  https://www.irisreservation.ca
Or send email to : martin.legault.hsc@ssss.gouv.qc.ca

Learning objectives

• Analyze the data emerging from the MPACT trial,
• Evaluate and differentiate current therapeutic options for the treatment of metastatic pancreatic cancer in Canada,
• Apply best practices for the evolving treatment of pancreatic cancer to improve patient outcomes.
**Learning objectives**

- Review the evidence for the use of chemotherapy in castrate sensitive prostate cancer
- Review management strategies for mCRPC in 2015
- Review ongoing and future directions in prostate cancer research
Dr Lecia V. Sequist  
Associate Professor  
Dana-Farber Cancer Institute  
Harvard Cancer Centre

“Molecularly defined lung cancers – Who’s who?”

Wednesday, February 25, 2015

Hôpital Notre-Dame  
1560, Sherbrooke East Street  
Auditorium Deschamps (Room I-1176-2)  
17:00 to 18:00

Thursday, February 26, 2015

Hôpital général juif  
3755, Côte Ste-Catherine Road  
Room E711 — 12:30 to 13:30

Inscription à la visioconférence:  

Learning objectives

- Which molecular features of lung cancer are relevant for therapy related decisions
- Discussion of first-line therapy paradigms
- When and how to treat after progression to first-line therapy
**Professor Dr Mathias Rummel**
Clinic for Hematology and Medical Oncology
Justus-Liebig University-Hospital
Gießen, Germany

"An update on the latest clinical evidence for the management of hematological malignancies"

**Wednesday, March 18, 2015**

**Lyman Duff Conference**
3775, University Street
Room 112
8:30 to 9:30

**Hôpital Maisonneuve-Rosemont**
5415, de l'Assomption boulevard
Pavillon Marcel Lamoureux Room – 080
12:00 to 13:00

**Hôpital Notre-Dame**
1560, Sherbrooke East Street
Auditorium Deschamps
17:00 to 18:00
Live on the Web!
[www.vpsolution.tv/vspo](http://www.vpsolution.tv/vspo)
Problems/Questions: 514 813-4510

**Thursday, March 19, 2015**

**Jewish General Hospital**
3755, Côte Ste-Catherine Road
Room E-711
12:30 to 13:30

**Hôpital du Sacré-Cœur de Montréal**
5400, Gouin West boulevard
Room-G4115
15:00 to 16:00
Visioconference: martin.legault.hsc@ssss.gouv.qc.ca
514 338-2222, x2574

**Friday, March 20, 2015**

**Hôpital Charles-Le Moyne**
3120, Taschereau boulevard
Room · HN-106 (CICM)
9:00 to 10:00
Visioconference:
caroline.boucher@rrssss16.gouv.qc.ca
450 466-5000, x3669

**Learning Objective**

- Summarize the current data available for the management of the various iNHL histological subtypes and MCL
- Debate the rationale of a maintenance therapy in the treatment of lymphoma
Dr Christian Kollmannsberger  
Oncologist  
British Columbia Cancer Agency  Vancouver Cancer Centre  
Clinical Professor  
University of British Columbia

Dr Denis Soulières  
Hemato-oncologist and Director, special hematology laboratory and molecular biology, CHUM  
Associate professor  
Departement of medicine University of Montreal

“Latest Evidence in mRCC”

Wednesday, April 1, 2015

Jewish General Hospital  
3755, Côte Ste-Catherine Road  
Room – E711  
*In visioconférence at the Montreal General Hospital – Room D14-102

Hôpital Notre-Dame  
1560, Sherbrooke East Street  
Auditorium Deschamps

In visioconférence:  

Live on the Web!  
www.vpsolution.tv/vspo

Problems/Questions:  
514 813-4510

Learning Objectives

- Evaluate approaches to the sequencing of therapies that optimize patient benefit and quality of life
- Summarize ongoing trials and novel therapies on the horizon for the treatment of mRCC
- Discuss the mechanism of resistance in therapy and potential strategies to address it
**Wednesday, April 22, 2015**

**Dr Malcolm Moore**
Program Head, Medical Oncology and Hematology PMH  
Professor, Department of Medicine and Pharmacology, University of Toronto  
Director, McCain Centre for Pancreatic Cancer

**“Recent Advances in Pancreatic Cancer”**

12:00 h to 13:00 h : Montreal General Hospital - 1650 Cedar Avenue - Room D14-102  

**Learning Objectives:**
- Provide an overview of pancreatic cancer in Canada
- Evaluate and differentiate current therapeutic options for the treatment of metastatic pancreatic cancer in Canada
- Discuss treatment options in earlier stages of pancreatic cancer (adjuvant, neo-adjuvant and locally advanced)

**“Advanced Pancreatic Cancer: A Case-based Discussion”**

17:00 h to 18:00 h : Hôpital Notre-Dame - 1560, Sherbrooke East Street - Auditorium Deschamps - Live on the Web!  
[www.vpsolution.tv/vspo](http://www.vpsolution.tv/vspo)  
Problems/Questions: 514 813-4510

**Learning Objectives:**
- To review the data that supports the utilization of chemotherapy in advanced pancreatic cancer
- To identify and discuss the impact of patient characteristics, such as age and performance status, on treatment selection for patients with advanced pancreatic cancer
- To review best practices for the management of patients on therapy for advanced pancreatic cancer
Professor Michel Ducreux, MD, PhD
Head of the Gastrointestinal Unit
Institut Gustave Roussy, France
Professor, University of Paris Sud

“Nouveautés en cancer colorectal métastatique, notamment sur les thérapies ciblées”

Wednesday, June 17, 17:00 to 18:00 – French Talk
Hôpital Notre-Dame, 1560, Sherbrooke East Street, Auditorium Deschamps
Live on the Web: www.vpsolution.tv/ppio - Problems/Questions: 514 813-4510

Learning Objectives:
• Évaluer les plus récentes données cliniques sur les thérapies ciblées en cancer colorectal métastatique et discuter de leur impact sur les algorithmes de traitement présentement utilisés dans la pratique clinique
• Identifier des stratégies thérapeutiques individualisées pour les patients atteints de cancer colorectal métastatique selon le statut mutationnel, les caractéristiques du patient et de sa maladie, et des préférences de celui-ci

“The role of maintenance therapy in mCRC and current clinical evidence for continued anti-VEGF inhibition following first progression in mCRC”

Thursday, June 18, 8:30 to 9:30 – English Talk
Jewish General Hospital, 3755, Côte-Sainte-Catherine Road, Room E-711

Learning Objectives:
• Evaluate the role of maintenance chemotherapy in mCRC
• Review the current clinical evidence for continued anti-VEGF inhibition following first progression in mCRC